Hypertrophic cardiomyopathy is the most common inherited heart disease and a leading cause of sudden cardiac death in young adults — yet therapeutic options remain frustratingly narrow. The only recently approved targeted therapy, mavacamten, carries meaningful safety restrictions. A new molecular candidate identified in preclinical research may open a fundamentally different avenue of intervention, one rooted in restoring the heart's own signaling chemistry rather than suppressing contractile function.
The study centered on ELABELA (ELA), an endogenous peptide that activates the apelin receptor APJ — a G-protein-coupled receptor with established roles in blood pressure regulation and cardiac development. Examining myocardial tissue from human HCM patients and two genetically distinct sarcomere-mutation mouse models, investigators found that ELA expression was substantially depleted in diseased hearts while APJ receptor expression paradoxically increased, suggesting compensatory upregulation of a starved signaling axis. Restoring ELA signaling via AAV9-mediated gene delivery or chronic peptide administration produced significant improvements across multiple cardiac endpoints: reduced pathological hypertrophy, decreased fibrosis, improved diastolic function, and normalized calcium transient dynamics in isolated cardiomyocytes — the calcium dysregulation being a central driver of HCM's hypercontractile phenotype.
The apelin/APJ axis has attracted growing cardiometabolic interest over the past decade, with earlier work linking apelin peptides to favorable effects in heart failure and pulmonary arterial hypertension. ELA, identified in 2013 as a second endogenous APJ ligand, is less studied but appears to have distinct receptor-binding kinetics. This study's strength lies in converging evidence across human tissue, two mouse models, and mechanistic in-vitro assays — a more rigorous multi-platform design than typical preclinical cardiovascular papers. However, critical limitations apply: all causal data are animal-derived, AAV9 delivery is not yet clinically viable for this indication, and peptide half-life in vivo remains a translation barrier. Whether ELA's benefits hold across the diverse sarcomere mutation landscape of human HCM remains untested. Nonetheless, the receptor-upregulation phenotype in human tissue lends biological plausibility. This represents an incremental but genuinely promising step toward endogenous peptide-based HCM therapy.